GERON CORP
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA, 94404
Mailing Address 919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA, 94404
Phone 6504737700
Fiscal Year End 1231
EIN 752287752
Financial Overview
FY2024
$313.46M
Total Liabilities
$-0.32
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| 8-K Current report of material events | January 12, 2026 | View on SEC |
| 8-K Current report of material events | January 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 8-K Current report of material events | December 16, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 7, 2025 | View on SEC |
| 8-K Current report of material events | November 5, 2025 | View on SEC |
| 4 Insider stock transaction report | October 20, 2025 | View on SEC |
| 3 Initial insider ownership report | October 20, 2025 | View on SEC |
| 8-K Current report of material events | October 14, 2025 | View on SEC |
Material Events
8-K Layoffs December 16, 2025
High Impact
- Geron Corp received FDA approval for Rytelo (imetelstat) in June 2024, marking a major milestone for its flagship product.
- In December 2025, Geron announced a strategic restructuring plan, including a workforce reduction.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.